Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [18F]FDG PET/CT study
Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment‑naïve HLA‑A*02:01+ patients with unresectable or metastatic uveal melanoma.
Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment‑naïve HLA‑A*02:01+ patients with unresectable or metastatic uveal melanoma (mUM).
The study demonstrates that AI‑assisted quantitative PET/CT can identify prognostic biomarkers (TMTV, TLG) and metabolic response to tebentafusp in mUM, guiding treatment decisions and risk stratification.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research